Analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for shares of PTC Therapeutics in a report released on ...

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest ...

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price ...

Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...

KBC Group NV raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 36.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a ...

PTC Therapeutics has undergone significant changes in recent months, including a major restructuring effort led by CEO Dr. Klein. This initiative has resulted in a 25% reduction in headcount and lower ...